[1] |
Zackheim HS, Amin S, Kashani⁃Sabet M, et al. Prognosis in cutaneous T⁃cell lymphoma by skin stage: long⁃term survival in 489 patients[J]. J Am Acad Dermatol, 1999, 40(3): 418⁃425.
|
[2] |
Guenova E, Watanabe R, Teague JE, et al. TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T⁃cell lymphoma[J]. Clin Cancer Res, 2013, 19(14): 3755⁃3763. DOI: 10.1158/1078⁃0432.CCR⁃12⁃3488.
|
[3] |
Skinnider BF, Elia AJ, Gascoyne RD, et al. Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed⁃Sternberg cells of Hodgkin lymphoma[J]. Blood, 2001, 97(1): 250⁃255. DOI: 10.1182/blood.V97.1.250.
|
[4] |
Chaouchi N, Wallon C, Goujard C, et al. Interleukin⁃13 inhibits interleukin⁃2⁃induced proliferation and protects chronic lymphocytic leukemia B cells from in vitro apoptosis[J]. Blood, 1996, 87(3): 1022⁃1029.
|
[5] |
Aspord C, Pedroza⁃Gonzalez A, Gallegos M, et al. Breast cancer instructs dendritic cells to prime interleukin 13⁃secreting CD4+ T cells that facilitate tumor development[J]. J Exp Med, 2007, 204(5): 1037⁃1047. DOI: 10.1084/jem.20061120.
|
[6] |
Diamandidou E, Cohen PR, Kurzrock R. Mycosis fungoides and Sézary syndrome[J]. Blood, 1996, 88(7): 2385⁃2409.
|
[7] |
Jokinen CH, Fromm JR, Argenyi ZB, et al. Flow cytometric evaluation of skin biopsies for mycosis fungoides[J]. Am J Dermatopathol, 2011, 33(5): 483⁃491. DOI: 10.1097/DAD. 0b013e31820595da.
|
[8] |
Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer[J]. J Clin Oncol, 2011, 29(18): 2598⁃2607. DOI: 10.1200/JCO.2010.32. 0630.
|
[9] |
Gabitass RF, Annels NE, Stocken DD, et al. Elevated myeloid⁃derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin⁃13[J]. Cancer Immunol Immunother, 2011, 60(10): 1419⁃1430. DOI: 10.1007/s00262⁃011⁃1028⁃0.
|
[10] |
Berzofsky JA, Terabe M. A novel immunoregulatory axis of NKT cell subsets regulating tumor immunity[J]. Cancer Immunol Immunother, 2008, 57(11): 1679⁃1683. DOI: 10.1007/s00262⁃008⁃0495⁃4.
|
[11] |
Nielsen M, Nissen MH, Gerwien J, et al. Spontaneous interleukin⁃5 production in cutaneous T⁃cell lymphoma lines is mediated byconstitutively activated Stat3[J]. Blood, 2002, 99(3): 973⁃977. DOI:10.1182/blood.V99.3.973.
|
[12] |
Geskin LJ, Viragova S, Stolz DB, et al. Interleukin⁃13 is overexpressed in cutaneous T⁃cell lymphoma cells and regulates their proliferation[J]. Blood, 2015, 125(18): 2798⁃2805. DOI: 10.1182/blood⁃2014⁃07⁃590398.
|
[13] |
Donaldson DD, Whitters MJ, Fitz LJ, et al. The murine IL⁃13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL⁃13 receptor alpha 1[J]. J Immunol, 1998, 161(5): 2317⁃2324.
|
[14] |
Wynn TA. IL⁃13 effector functions[J]. Annu Rev Immunol, 2003,21: 425⁃456. DOI: 10.1146/annurev.immunol.21.120601.141142.
|
[15] |
Husain SR, Joshi BH, Puri RK. Interleukin⁃13 receptor as a unique target for anti⁃glioblastoma therapy[J]. Int J Cancer, 2001, 92(2): 168⁃175. DOI: 10.1002/1097⁃0215(200102)9999:9999<::AID⁃IJC1182>3.0.CO;2⁃N.
|
[16] |
Kioi M, Husain SR, Croteau D, et al. Convection⁃enhanced delivery of interleukin⁃13 receptor⁃directed cytotoxin for malignant glioma therapy[J]. Technol Cancer Res Treat, 2006, 5(3): 239⁃250. DOI: 10.1177/153303460600500307.
|